|Bid||6.27 x 0|
|Ask||6.31 x 0|
|Day's Range||6.10 - 6.42|
|52 Week Range||1.98 - 9.25|
|Beta (5Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.05|
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20th Annual Biotech in Europe Forum held on September 21-24, 2020.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the IMV’s executive management team will participate at four upcoming virtual investor conferences in September: